Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the
enzymes needed for cell growth. Giving imatinib mesylate after a donor stem cell transplant
may prevent the recurrence of Philadelphia chromosome-positive leukemia.
PURPOSE: This phase I/II trial is studying the side effects of giving imatinib mesylate after
a donor stem cell transplant and to see how well it works in treating patients with
Philadelphia chromosome-positive leukemia.